Inflammation: Oncostatin M blockade attenuates colitis
Nature Reviews Drug Discovery 16, 386 (2017).
doi:10.1038/nrd.2017.100
Author: Sarah Crunkhorn
Anti-tumour necrosis factor (TNF) antibodies represent established therapies for inflammatory bowel disease (IBD), but up to 40% of patients exhibit primary nonresponsiveness to anti-TNF agents, and resistance can develop. West et al. observe high levels of the cytokine oncostatin M (OSM) and its receptor
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
More News: Drugs & Pharmacology | Inflammatory Bowel Disease